Formosa Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 13, 2021 at 05:33 pm EDT
Share
Formosa Laboratories, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was TWD 736.279 million compared to TWD 662.643 million a year ago. Operating loss was TWD 69.014 million compared to TWD 48.415 million a year ago. Net income was TWD 1,065.812 million compared to net loss of TWD 101.880 million a year ago. Basic earnings per share was TWD 9.84 compared to basic loss per share of TWD 1.03 a year ago. Diluted earnings per share was TWD 8.78 compared to diluted loss per share of TWD 1.03 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
FORMOSA LABORATORIES, INC. 
